Other substances

Dasatinib

Phase of research

Potential treatment - theoretical effect

How it helps

Other treatment

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States Preprint	in silico		one of the top drugs and compounds identified by ViroTreat	May/17/2020

AI-suggested references

Link	Publication date
Virus-induced senescence is a driver and therapeutic target in COVID-19.	Sep/13/2021
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19	Aug/28/2020
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK	Mar/08/2022
The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro	Dec/04/2020
Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19	May/20/2021
High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain	Dec/14/2021
Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease	Apr/08/2022
An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 omicron inhibitors	Apr/22/2022

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04830735	Dasatinib for the Treatment of Moderate and Severe COVID-19	Not yet recruiting	Phase 2	Dec/15/2021	Dec/15/2024
Alternative id - 0S-20-5\|NCI-2020-04367\|P30CA014089 Interventions - Drug: Dasatinib Anhydrous\|Drug: Placebo Administration Study type - Interventional Study results - No Results Available Locations - USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 144 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of participants requiring invasive mechanical ventilation, requiring tocilizumab or dying\|Absolute lymphocyte count\|CRP (C-reactive protein) level\|Change of the SOFA (Sequential Organ Failure Assessment)\|Number of participants with treatment-related side effects\|Radiological response\|Duration of hospitalization\|Remission of respiratory symptoms